CDX2 and neoplasm: Exploratory analyses suggested that the benefit from chemotherapy in the RCC2-low subgroup was independent of CDX2 expression, but the number of tumours with low CDX2 expression was too small to draw a firm conclusion (online supplemental figure 13).